186 related articles for article (PubMed ID: 15613925)
1. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
Koestenberger M; Cvirn G; Gallistl S; Muntean W
Blood Coagul Fibrinolysis; 2004 Oct; 15(8):693-7. PubMed ID: 15613925
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Koestenberger M; Cvirn G; Gallistl S; Kutschera J; Muntean W
Acta Paediatr; 2005 Jul; 94(7):884-9. PubMed ID: 16188810
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
Koestenberger M; Cvirn G; Gallistl S; Baier K; Leschnik B; Muntean W
J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
[TBL] [Abstract][Full Text] [Related]
5. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
6. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
7. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
[TBL] [Abstract][Full Text] [Related]
8. The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma.
Cvirn G; Gallistl S; Koestenberger M; Baier K; Fritsch P; Greilberger J; Jürgens G; Muntean W
Thromb Haemost; 2004 May; 91(5):912-8. PubMed ID: 15116251
[TBL] [Abstract][Full Text] [Related]
9. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
[TBL] [Abstract][Full Text] [Related]
12. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition.
Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Rehak T; Leschnik B; Muntean W
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):131-7. PubMed ID: 15091000
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
[TBL] [Abstract][Full Text] [Related]
15. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
Fenyvesi T; Jörg I; Weiss C; Harenberg J
Thromb Res; 2003; 111(1-2):89-94. PubMed ID: 14644085
[TBL] [Abstract][Full Text] [Related]
16. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
[TBL] [Abstract][Full Text] [Related]
18. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Furugohri T; Morishima Y
Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
[TBL] [Abstract][Full Text] [Related]
20. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
